Ixekizumab is a high-affinity monoclonal antibody against interleukin-17A. In patients with psoriatic arthritis, ixekizumab was better than adalimumab in treating skin disease (PASI 100). Similar improvements in joint disease (ACR20/50/70). Dr. Josef Smolen #ACR19 @RheumNow https://t.co/BriY8o10Hq